Abstract: Provided herein are purification, production and manufacturing methods for recombinant viral vector particles such as recombinant adeno-associated viral (rAAV) vector particles substantially free of empty viral particles; a population of recombinant adeno-associated vims (rAAV) particles purified using the method described herein, and a pharmaceutical composition comprising the purified rAAV.

Abstract: The present disclosure describes improved methods for use in purifying biological products made by host cells. In some embodiments, the improved methods comprise one or more steps of lysing host cells, such as with a detergent, to release the biological product, precipitating host cell DNA, such as with domiphen bromide, and then inhibiting precipitation of residual host cell DNA in a supernatant containing the biological product by adding a salt to a sufficient final concentration. In some embodiments, the biological product is a vaccine, or a viral vector for gene therapy, such as an AAV vector or a lentiviral vector.